Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

NCT05174832 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

136

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Cisplatin
DRUG: Nab-paclitaxel
DRUG: Pembrolizumab
DRUG: Olaparib

Sponsor

Fudan University

Collaborators

[object Object]